Posted by Michael Wonder on 27 Jun 2016
Health Canada approves first treatment for schizophrenia dosed four times a year
27 June 2016 - 93% of patients treated with Invega Trinza remained relapse-free at the end of long-term relapse prevention trial.
Janssen Inc. announced today Health Canada has approved Invega Trinza (paliperidone palmitate), an antipsychotic medication for schizophrenia, which provides a new dosing regimen option administered only four times a year — the longest timing available between doses.
Invega Trinza, a 3-month injection, is indicated for the treatment of schizophrenia in adult patients. Invega Trinza is to be used only after Invega Sustenna (1-month paliperidone palmitate prolonged-release injectable suspension) has been established as adequate treatment for at least four months. In order to establish a consistent maintenance dose, it is recommended that the last two doses of Invega Sustenna be the same dosage strength before starting Invega Trinza. Health Canada approved Invega Sustenna for the treatment of schizophrenia in 2010.
